

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/712,296	11/14/2003		Tinya Abrams	PC23579A	8864
28940	7590	12/12/2006		EXAMINER	
PFIZER IN		TED DOUE	GEMBEH, SHIRLEY V		
10555 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121				ART UNIT	PAPER NUMBER
				1614	
•	$\gamma = \delta$			DATE MAILED: 12/12/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)						
	10/712,296	ABRAMS ET AL.						
Office Action Summary	Examiner	Art Unit						
	Shirley V. Gembeh	1614						
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address						
	·	C) OD THIDTY (20) DAYO						
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period or - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timwill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).						
Status								
1)⊠ Responsive to communication(s) filed on <u>31 M</u>	farch 2006							
·_ ·	action is non-final.							
,— ,	· · · · · · · · · · · · · · · · · · ·							
closed in accordance with the practice under E								
Disposition of Claims		•						
4)⊠ Claim(s) <u>1-12,17-19 and 21-25</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdra	4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) 21-25 is/are allowed.								
6)⊠ Claim(s) <u>1-11 and 17-18</u> is/are rejected.	⊠ Claim(s) <u>1-11 and 17-18</u> is/are rejected.							
7)⊠ Claim(s) <u>12 and 19</u> is/are objected to.	☑ Claim(s) <u>12 and 19</u> is/are objected to.							
8) Claim(s) are subject to restriction and/c	or election requirement.	•						
Application Papers								
9)☐ The specification is objected to by the Examine	er.							
10)☐ The drawing(s) filed on is/are: a)☐ acc	epted or b) objected to by the	Examiner.						
Applicant may not request that any objection to the								
Replacement drawing sheet(s) including the correct		•						
11)☐ The oath or declaration is objected to by the E	xaminer. Note the attached Office	Action or form PTO-152.						
Priority under 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a	)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:								
1. Certified copies of the priority document								
2. Certified copies of the priority document								
3. Copies of the certified copies of the prior		ed in this National Stage						
application from the International Burea  * See the attached detailed Office action for a list	` ''	ad						
See the attached detailed Office action for a list	or the certified copies flot receive	· ·						
Attachment(s)	·							
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> </ol>	4) Interview Summary Paper No(s)/Mail D							
<ul> <li>2) Into Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ul>	5) Notice of Informal F							

Art Unit: 1614

**DETAILED ACTION** 

Page 2

**Status of Claims** 

Claims 1 and 17 have been amended and claims 21-25 have been newly added.

Claims 1-12, 17-19 and 21-25 are now pending.

Claims 13-16 and 20 have been cancelled.

The response filed March 31, 2006 presents remarks and arguments to the office action mailed January 04, 2006. Applicants' request for reconsideration of the rejection of claims in the last office action has been considered.

Applicants' arguments, filed March 31, 2006, have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Claim Objections

Claims 12 and 19 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Allowable Subject Matter

Claims 21-25 are allowed.

Claim Rejections - 35 USC § 112

Art Unit: 1614

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-11 and 17-18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

This is a written description rejection.

A lack of adequate written description issue arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not "reasonably lead" those skilled in the art to any particular species); In re Ruschig, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967).

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a

Art Unit: 1614

combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.

A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]."

Applicant has not provided a description of the structure of a representative number of compounds nor a description of the chemical and/or physical characteristics of a representative number of compounds nor a description of how to obtain a representative number of specific compounds.

In other words, the Applicant has not described with sufficient clarity a microtubule interference agents, topoisomerase inhibitors, alkylating agents, thymidylate synthase inhibitors, irreversible steroidal aromatase inactivators, anti-metabolites, pyrimidine antagonist, purine antagonists ribonucleotide reductase inhibitors, and kinase inhibitors.

Employing these agents as listed above are not described nor exemplified and does not provide written description of such agents. For example, there are numerous kinase inhibitors, surely not every kinase inhibitor will effect the instant compound of formula I in a synergistic or at most an additive way.

Art Unit: 1614

Page 5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shirley V. Gembeh whose telephone number is 571-272-8504. The examiner can normally be reached on 8:30 -5:00, Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

SVG 11/30/06

ARDIN H. MARSCHEL SUPERVISORY PATENT EXAMINER

U. Warshel 12/8/06